Endobronchial Ultrasound Biopsy Device Market Size is likely to make a steady headway from 2022 to 2028, pushed by the rising lung cancer prevalence across the globe. The increasing degree of indoor and outdoor air pollution has been a key contributor to the high incidence of lung cancer across countries such as China and India. As endobronchial ultrasound (EBUS) biopsy procedure is a minimally invasive surgery that can accurately diagnose lung conditions including cancer, infection, and inflammation, EBUS devices market share is recording a high growth rate worldwide.
Endobronchial ultrasound biopsy device market share from the bronchoscopes & probes segment is slated to grow at an appreciable CAGR between 2021 and 2028. The rising demand for transbronchial biopsy procedures is one of the leading drivers of the bronchoscopy market. Product uptake is rising due to the rising incidence of respiratory illnesses such as chronic obstructive pulmonary disease (COPD), blockages, bronchopulmonary hemorrhage, and tumors, especially amongst the elderly population.
By end use, the industry share is divided into diagnostic centers, hospitals, ambulatory surgical centers, and specialty centers. The endobronchial ultrasound biopsy device industry share from the specialty centers is slated to rise significantly over the analysis period, due to the increased reliance on expertise provided by surgeons, pulmonologists, technologically equipped infrastructure, and latest solutions such as lung transplants. These centers offer interventional pulmonology services, which eliminate the need for open surgery.
France endobronchial ultrasound biopsy device market size is set to grow at a considerable pace through the forecast timeline. According to the 2020 GLOBOCAN report by the International Agency for Research on Cancer, there were nearly 48299 new cases of lung cancer across the nation during 2020. The availability of medical reimbursements is ensuring that more patients avail of these procedures.
Clinodevice, Medtronic Plc, Boston Scientific Corporation, Olympus Corporation, Veran Medical technologies, and Conmed are some leading biopsy device manufacturers in the global market. These companies are diversifying their product portfolios by launching innovative products. In May 2021, Olympus Medical Systems Group announced that it has received FDA clearance for its new endobronchial ultrasound bronchoscope. The product exhibits high sensitivity and specificity, resulting in higher diagnostic yield for minimally invasive lung cancer detection.
During 2020, the industry suffered tremendous losses owing to the shutdown of manufacturing units. Suspension of non-urgent hospital procedures had a severe impact on the market as well, since patients had been avoiding hospital visits. However, emergence of new opportunities is evident since the easing of lockdowns. As individuals suffering from respiratory disorders are deemed as high-risk patients if they contract the SARS-CoV-2 virus, the R&D funding for developing advanced EBUS biopsy devices has been growing, supporting the industry outlook.
Market, by Application
Market, by End-use
The above information is provided for the following regions and countries: